GeoVax Labs Inc. (NASDAQ:GOVX) Shares Shorted: Short Interest Down 43.5% in September

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest totaling 281,773 shares, a decrease of 43.5% from the September 15th total of 498,698 shares. Approximately 3.8% of the company’s stock are sold short. Based on an average daily volume of 241,876 shares, the days-to-cover ratio is presently 1.2 days.

GeoVax Labs Stock Performance

GOVX stock traded up $0.00 during trading on Thursday, reaching $0.24. 577,092 shares of the company were exchanged, compared to its average volume of 1,913,438. The stock’s 50 day moving average price is $0.49 and its 200 day moving average price is $1.07. GeoVax Labs has a 52-week low of $0.23 and a 52-week high of $15.75. The company has a market cap of $1.81 million, a P/E ratio of -0.02 and a beta of 3.69.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings results on Monday, July 27th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($2.16) by $1.19. As a group, equities research analysts forecast that GeoVax Labs will post -4.94 EPS for the current year.

Analyst Upgrades and Downgrades

GOVX has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research report on Friday, July 17th. Wall Street Zen raised GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Sunday, June 21st. Finally, Noble Financial reiterated an “outperform” rating on shares of GeoVax Labs in a research note on Tuesday, September 15th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $150.00.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and cancer. The company’s research is based primarily on a vaccine platform that combines a modified vaccinia Ankara (MVA) viral vector with virus-like particles (VLPs) to stimulate both antibody and cellular immune responses.

GeoVax’s development programs have included GEO-CM04S1, a next-generation COVID-19 vaccine candidate; GOVX-B11, an investigational HIV vaccine designed to generate broadly protective immune responses; and GOVX-CHIKV, a vaccine candidate targeting chikungunya virus.